Clinical trial
SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
NCT00335166 · Solvay Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00335166 |
|---|---|
| Title | SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease |
| Official title | A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease. |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Early Stage Parkinson Disease |
| Intervention type | Drug |
| Interventions | Pardaprunox, pramipexole, Placebo Comparator |
| Enrollment | 330 |
| Start date | Nov 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Jun 9, 2006 |
| Last update posted | Apr 3, 2008 |
| Countries | Australia, Czechia, Estonia, France, Germany, India, Italy, Lithuania, Malaysia, Netherlands, Poland, Portugal and 6 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: